291 related articles for article (PubMed ID: 27357507)
1. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA;
Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507
[TBL] [Abstract][Full Text] [Related]
2. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
[TBL] [Abstract][Full Text] [Related]
4. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania.
Duchovskiene N; Mickeviciene D; Jurkeviciene G; Dirziuviene B; Balnyte R
Mult Scler Relat Disord; 2017 Apr; 13():107-111. PubMed ID: 28427690
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
7. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
8. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Cascione M; Tenenbaum N; Wendt J; Meng X; Schofield L; Cree BAC;
Mult Scler Relat Disord; 2018 Oct; 25():50-56. PubMed ID: 30036854
[TBL] [Abstract][Full Text] [Related]
9. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
11. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
12. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
[TBL] [Abstract][Full Text] [Related]
13. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
[TBL] [Abstract][Full Text] [Related]
14. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
15. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
Higuera L; Carlin CS; Anderson S
J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
[TBL] [Abstract][Full Text] [Related]
16. Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.
McKay KA; Evans C; Fisk JD; Patten SB; Fiest K; Marrie RA; Tremlett H
Neuroepidemiology; 2017; 48(3-4):124-130. PubMed ID: 28683461
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
18. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
[TBL] [Abstract][Full Text] [Related]
19. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B
Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325
[TBL] [Abstract][Full Text] [Related]
20. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
